Arcturus, a new COVID-19 sub-variant, has caught the attention of the World Health Organization (WHO). The new omicron variant, XBB.1.16, causes familiar symptoms of previous variants of coronavirus.

Arcturus’ lead clinical stage product candidates include a first-in-class, self-amplifying mRNA vaccine for COVID-19 and an mRNA replacement therapy for ornithine transcarbamylase (OTC ...

The Arcturus subvariant stems from the Omicron strain of Covid-19 and is known as XBB.1.16 since it descends from the recombinant variant XBB, which combines two sublineages of Omicron BA.2.

The Ministry of Health, Labour and Welfare (MHLW) gave the green light to CSL and Arcturus’ COVID-19 vaccine ARCT-154 – also known as Lunar-COV19 – which will be commercialised in Japan by ...

Additionally, Arcturus’s robust pipeline, including ARCT-154 for COVID-19, ARCT-810 for OTC deficiency, and ARCT-032 for cystic fibrosis, demonstrates promising risk-adjusted per share values.

The Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing ("Rospotrebnadzor") sees a risk of the increased incidence of infections with the Arcturus COVID-19 ...

Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine ...